Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
111 Results for "
Chimeras.
" in MedChemExpress (MCE) Product Catalog:
Products (111)
111 Results for "Chimeras." in MCE Product Catalog:
Cat. No.: HY-175562
Research Areas:
LDH-IN-4 is a LDHA and LDHB inhibitor, as well as a ligand for target protein for PROTACs. LDH-IN-4 can be used to synthesize proteolysis-targeting chimeras (PROTAC), such as MS6105 (HY-152261). LDH-IN-4 is applicable to pancreatic cancer-related research .
Cat. No.: HY-183724
CAS No.: 3060517-63-4
Target:
Research Areas:
MS8572 is a selective OTUB1 covalent ligand. MS8572 covalently modifies the noncatalytic cysteine 23 residue of OTUB1 and does not inhibit OTUB1 deubiquitinase activity. MS8572 can be used for development of deubiquitinase-targeting chimeras for targeted protein stabilization .
Cat. No.: HY-183981
Target:
Research Areas:
RNA binder 4 is an RNA-binding agent that can be used for the synthesis of MJ-NR-27 (HY-183980). MJ-NR-27 is a bifunctional ribonuclease-targeting chimera (RIBOTAC) small molecule that targets NRAS mRNA containing a G-quadruplex structure, and it can be used in cancer research .
Cat. No.: HY-184176
Target:
Research Areas:
DBCO-PEG3-AP1867 is a bifunctional molecular building block that binds to FKBP12 F36V, and also a SPAAC-compatible reagent suitable for synthesizing O-GlcNAcylation-targeting chimeras (OGTACs) against c-Myc. DBCO-PEG3-AP1867 is applicable to cancer-related research .
Cat. No.: HY-184505
CAS No.: 2790482-16-3
(±)-trans-BAS-2 is a hHDAC6 inhibitor with an IC50 value of 0.462 μM. (±)-trans-BAS-2 serves as a scaffold for the design of proteolysis-targeting chimeras (PROTACs) and induces proteasome-dependent degradation of hHDAC6 in cells. (±)-trans-BAS-2 can be used in the research of triple-negative breast cancer and multiple myeloma .
Cat. No.: HY-185122
CAS No.: 3060520-53-5
MS6178 is a MS5105-based CFTR deubiquitinase-targeted chimera (DUBTAC) that recruits OTUB1 to stabilize ΔF508-CFTR mutant protein in a concentration- and time-dependent manner, with an OTUB1-dependent effect and no impact on CFTR mRNA level. MS6178 can be used for the research of cancer .
Cat. No.: HY-101460R
CAS No.: 2087490-42-2
Research Areas:
Tz-Thalidomide (Standard) is the analytical standard of Tz-Thalidomide (HY-101460). This product is intended for research and analytical applications. Tz-Thalidomide is a tetrazine-tagged Thalidomide (HY-14658), an E3 ligase ligand. Tz-Thalidomide self-assembles with TCO-labeled target protein inhibitors, forming a CLIP-TAC (targeted protein degradation chimera) via click chemistry. This chimera recruits the E3 ubiquitin ligase CRBN to the target protein, thereby inducing ubiquitination and subsequent degradation of the target protein. When used in combination with JQ1-TCO (HY-148864), Tz-Thalidomide induces concentration-dependent degradation of BRD4 in cells. When combined with ERK-targeting protein inhibitors, Tz-Thalidomide induces degradation of ERK1/2 in cells. Tz-Thalidomide can be used in cancer-related research .
Cat. No.: HY-164396
CAS No.: 3030990-46-3
Target:
Research Areas:
Allyl-mannose-6-phosphonate is a stable analog of mannose-6-phosphate (M6P). Allyl-mannose-6-phosphonate can be used to synthesize M6Pn-polypeptide conjugates and construct lysosome-targeting chimeras (LYTAC). Allyl-mannose-6-phosphonate is applicable for tumor research .
Cat. No.: HY-183725
CAS No.: 3060520-82-0
Target:
Research Areas:
MS5128 is an OTUB1-based deubiquitinase-targeting chimera (DUBTAC) targeting CFTR. MS5128 recruits OTUB1 to CFTR to induce deubiquitination and stabilization of CFTR. MS5128 can be used for the research of cystic fibrosis . (Blue: CFTR Ligand (HY-183724); Pink: OTUB1 Ligand (HY-13262); Black: Linker)
Cat. No.: HY-W947273
CAS No.: 2766178-72-5
Target:
Research Areas:
CRBN ligand-898 is a CRBN ligand with a Kd of 216 nM. CRBN ligand-898 binds to CRBN, and when incorporated into proteolysis targeting chimeras (PROTACs), mediates degradation of intended target proteins. CRBN ligand-898 does not induce degradation of IMiD-associated neosubstrates Ikaros (IKZF1) and Aiolos (IKZF3). CRBN ligand-898 can be used to synthesize PROTACs .
Cat. No.: HY-184774
CAS No.: 1551528-06-3
Target:
Research Areas:
tri-GalNAc-C10-COOH (P290 232) is a targeted delivery intermediate composed of a trivalent N-acetylgalactosamine (GalNAc) cluster attached to a C10 linker ending with a carboxylic acid (-COOH) group. tri-GalNAc-C10-COOH is a standard building block used to synthesize LYTACs (lysosome-targeting chimeras) and cell-specific oligonucleotides like siRNA or ASO therapeutics .
Cat. No.: HY-181830
Target:
Research Areas:
Atz-L5 is a PD-L1 PTAC (PSMA-targeted chimera) degrader (DC50: 18 pM in PC3-PIP cells; 2 pM in LNCaP cells) and LYTAC. Atz-L5 promotes lysosomal degradation of PD-L1 in PSMA-positive prostate cancer cells. Atz-L5 is applicable to the research of prostate cancer .
Cat. No.: HY-181495
CAS No.: 2375455-53-9
Research Areas:
RAJQ14 is a BRD4 PROTAC-like CAP-TAC (Proteasome Cap Targeting Chimeras) degrader. RAJQ14 binds to 19S proteasome cap subunits RPN1, RPN10, RPN13, and USP14 to recruit target proteins to the proteasome for ubiquitination-independent, proteasome-dependent degradation. RAJQ14 can be used for the research of cancer (Pink: BRD4 Ligand (HY-181496); Blue: Proteasome Ligand (HY-128978); Black: Linker).
Cat. No.: HY-181829
Ctx-L3 is a selective EGFR PTAC (PSMA-targeted chimera) degrader (DC50: 4.3 pM in LNCaP cells) and LYTAC. Ctx-L3 recruits prostate-specific membrane antigen (PSMA) and mediates lysosomal degradation of EGFR in PSMA-positive prostate cancer cells. Ctx-L3 exhibits degrading activity against EGFR in prostate cancer cells. Ctx-L3 is applicable to related research on prostate cancer .
Cat. No.: HY-183061
Target:
Research Areas:
MrTAC-8, methylarginine-targeting chimera (MrTAC), is a BRD4 degrader with DC50 values of 46 nM in HeLa cells. MrTAC-8 recruits PRMT1, PRMT3, PRMT4, PRMT5, and PRMT7 to target proteins, inducing arginine methylation that triggers lysosomal degradation. MrTAC-8 degrades proteins across diverse subcellular localizations and independent of native proteolytic routes. MrTAC-8 can be used for the research of cervical cancer, glioblastoma .
Cat. No.: HY-183988
Target:
Research Areas:
OICR409946 is a self-dimerization-induced proximity-targeting chimera (SDIPTAC) targeting DCAF1, with a Kd value of 6200 nM. OICR409946 binds to DCAF1, induces head-to-tail homodimerization, sterically blocks the Vpr binding interface, prevents the recruitment of Vpr to the CRL4DCAF1 complex, and inhibits Vpr-dependent HIV replication. OICR409946 can be used in studies related to HIV infection (DCAF1 ligand: (HY-169390); Linker: (HY-130659)) .
Cat. No.: HY-145388R
CAS No.: 2380274-50-8
Research Areas:
AU-15330 (Standard) is the analytical standard of AU-15330 (HY-145388). This product is intended for research and analytical applications. AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide. AU-15330 induces disease remission in castration-resistant prostate cancer (CRPC) models without toxicity .
Cat. No.: HY-184160
Target:
Research Areas:
Mcl1 Degrader-1 is an autophagy-targeting chimera (AUTAC) that selectively degrades the Mcl1 protein. Mcl1 Degrader-1 mediates K63 ubiquitination of Mcl1 via TRAF6/UBC13, transports it to autolysosomes for degradation through p62/SQSTM1, and activates Beclin1-dependent autophagy. Mcl1 Degrader-1 can be used in studies related to multiple myeloma and non-small cell lung cancer .
Cat. No.: HY-183980
Target:
Research Areas:
MJ-NR-27 is a bifunctional small molecule of ribonuclease-targeting chimera (RIBOTAC) that targets NRAS mRNA containing a G-quadruplex structure. MJ-NR-27 uses RNase L ligand 3 (HY-177030) as the RNase L ligand, RNA binder 4 (HY-183981) as the RNA binder, and Bis-PEG3-acid (HY-126891) as the linker. MJ-NR-27 achieves target RNA degradation by recruiting ribonuclease RNase L, and significantly induces morphological changes in tumor cells. MJ-NR-27 can be used in cancer research .
Cat. No.: HY-L151
544 compounds
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy.
MCE supplies a unique collection of 544 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
